On Being with Krista Tippett

Episode: Gül Dölen – Psychedelic Science and Radical Healing

Release Date: March 5, 2026
Host: Krista Tippett
Guest: Dr. Gül Dölen

Overview

This episode explores the revolutionary frontiers of psychedelic science and its implications for radical healing, particularly concerning deep trauma, PTSD, addiction, and depression. Neuroscientist Dr. Gül Dölen shares her research on how psychedelically assisted therapies are revealing powerful truths about the brain's capacity to change—challenging psychiatric orthodoxy and offering both promise and caution. The discussion touches on the mechanisms of critical periods in the brain, the importance of integrating indigenous wisdom, and the real-world alliance forming for psychedelic research across political and social divides.

Key Discussion Points & Insights

1. Setting the Stage: Trauma, Psychedelics, and Hope

• Widespread Trauma: Krista opens by noting how trauma is omnipresent in society, and research into psychedelics offers a "stunning ray of hope in a struggling world." (00:00)
• A Careful Approach: She emphasizes both the risks and incredible potential of these substances—"Like all forces of great power, these can cut in every direction, the dark and the light of the human condition." (00:44)

2. Gül Dölen's Journey: From Texas to the Cutting Edge

• Personal Background: Gül, born in Buffalo, NY, raised in Texas, with deep family roots in Turkey and a lineage of academics, developed early curiosity about the mind. (04:08–05:01)
• Academic Evolution: Initially drawn to study consciousness through multiple disciplines (neuroscience, linguistics, philosophy, art), Gül pivoted fully to neuroscience after a revelatory course on psychoactive substances. (05:28–07:03)
  • “I felt like this is the way we're going to someday answer the big questions about consciousness.” — Gül Dölen (07:05)

3. Understanding Psychedelic Substances

• Terminology: MDMA (ecstasy), LSD, psilocybin, ayahuasca, ibogaine—different compounds but all potentially healing in specific, controlled settings. (09:43–12:35)
  • “These are just other substances, very powerful ones.” — Krista Tippett (12:35)
  • Gül clarifies naming confusion and notes MDMA’s unique “empathogenic” property: “heart opening.” (10:09–11:34)

4. Shifting Paradigms in Psychiatry and Neuroscience

• From Biochemical Fix to Experience-Based Change:
  • The historic model—SSRIs for “chemical imbalance"—is overly simplistic. Psychedelics suggest that “restoring the ability of the brain to learn” is central, not just rebalancing chemicals. (13:37–16:23)
  • “What psychedelics are teaching us is that that is not right.” — Gül Dölen (13:52)
• Durability of Healing: Psychedelic-assisted therapy can result in dramatic and lasting transformation—contrasting sharply with chronic pharmaceutical use. (16:23–17:25)

5. Critical Periods: The Brain’s Window of Change

• Definition and Importance:
  • “Critical periods,” coined by Lorenz in 1935, are limited windows during development when the brain is particularly receptive to learning certain skills or behaviors. (17:51–19:58)
• Neuroscience Obsession:
  • The struggle to cure brain diseases is often due to intervening after the critical period has closed.
  • “Neuroscientists have dreamt about having a way to reopen critical periods and then be able to treat diseases of the brain.” — Gül Dölen (20:02)
• Language and Social Learning:
  • Examples include visual development, language acquisition, and—Gül’s research focus—social learning and behavior. (20:10–21:08)

6. Mechanisms of Psychedelic Therapy

• Reopening Critical Periods:
  • New research suggests psychedelics can temporarily “reopen” these periods, allowing for deep relearning and emotional healing when paired with therapy. (21:08–22:29)
  • “If what you're doing is reopening critical periods, this is exactly the kind of recovery you would expect.” — Gül Dölen (22:26)
• Drug-Specific Effects:

  • Different psychedelics vary in how long they keep this critical period open:

    • Ketamine: 48 hours
    • MDMA/Psilocybin: ~2 weeks
    • LSD: ~3 weeks
    • Ibogaine: At least 4 weeks (24:58–26:28)

  • "The window of time is your opportunity to lock in whatever insights, whatever new habits that you're trying to form.” — Gül Dölen (27:38)

7. The Necessity of Setting and Integration

• It’s Not a “Magic Pill”:
  • Real transformation requires work after the psychedelic experience—integrating new perspectives, building new habits.
  • “The therapy or the work actually began the day after the trip.” — Veterans’ experience recounted by Gül Dölen (28:56)
• Ibogaine:
  • Not recreational; serious risks (e.g., cardiac arrest); transforms entrenched addiction/PTSD, but must be administered with caution. (29:50–31:01)

8. Potential Dangers and Ethical Responsibilities

• Neuroplasticity Cuts Both Ways:

  • While the brain's flexibility enables healing, “not all plasticity is good.” Addictive drugs can create "hyperplasticity" that entrenches harmful behaviors. (31:01–33:08)

• Vulnerable Populations:

  • Caution is critical for those with conditions like autism and schizophrenia, where critical periods may not close properly. (33:08)

9. Cultural Integration and Indigenous Wisdom

• Ethics of Appropriation:
  • Respect for indigenous practices, but also the necessity of understanding mechanisms within Western frameworks to ensure safe and effective use. (34:10–36:12)
  • “We can't just pluck something from another culture and expect to use it the way that we understand disease.” — Gül Dölen (35:06)

10. Societal, Structural, and Political Dynamics

• Therapist Training & Medical Models:

  • High standards for therapist training are vital. Psychedelic medicine may follow neurological rehab models, integrating therapy with intervention. (41:27–45:51)

• Political Alliances:

  • Remarkable bipartisan support: Texas devoting $50 million for ibogaine research, support from figures ranging from Rick Perry to Appalachian activists to military generals. (58:28–61:04)
  • “This is bipartisan... it’s very moving.” — Gül Dölen (61:04)

• Societal Acceptance & Cautions:

  • Need for measured, evidence-based advocacy—no “miracle pill” narratives. Risks of disappointment or misuse if the movement moves too fast. (55:33–58:28)
  • “I really, really, really don't want to set us up for the next fentanyl face plant.” — Gül Dölen (58:06)

11. Notable Research and Curiosities: The Octopus Study

• Serotonin Across Evolution:
  • Gül recounts a critical, playful experiment: administering MDMA to a normally asocial, combative octopus species made them sociable—suggesting deep evolutionary roots of serotonin’s social effects. (63:47–66:00)
  • “All of these brain areas and this anatomy is just sort of secondary, an accident of evolutionary history.” — Gül Dölen (65:18)
  • The importance of curiosity-driven science: “The way you discover the really big things is... asking, I wonder what would happen if." (65:44)

Notable Quotes

• On the paradigm shift in psychiatry:
  “What psychedelics are teaching us is that that is not right. And that instead... you can restore the ability of the brain to learn.” — Gül Dölen (13:52)
• On integrating new insights:
  “The therapy or the work actually began the day after the trip, because it was the day after that I had to take those insights and build them back into all the ways I interact with the world.” — Gül Dölen (28:56)
• On neuroplasticity:
  “Not all plasticity is good plasticity.... What psychedelics seem to be doing is enabling a change so that the same stimulus is able to induce plasticity more easily. That is called metaplasticity.” — Gül Dölen (31:01)
• On cultural stewardship:
  “For the plant medicines, surely we have borrowed from other cultures, but MDMA and LSD and ketamine and PCP are synthetic compounds that we are the knowledge keepers of.” — Gül Dölen (35:50)
• On political alliances:
  “There was this bizarre... bipartisan, not just dialogue, but like this shared passion for making something happen and actually for making healing happen.” — Krista Tippett (58:28)

Selected Timestamps for Key Segments

• Intro & Framing the Episode – 00:00–04:08
• Gül’s Background & Early Academic Interests – 04:08–07:03
• Psychedelic Drug Terminology & Classifications – 09:43–12:35
• Paradigm Shift: From SSRIs to Psychedelic Therapy – 13:37–16:23
• Critical Periods Explained & Importance in Healing – 17:51–21:08
• Mechanisms: Reopening Critical Periods with Different Substances – 24:58–27:53
• Therapy & the Importance of Integration Work – 27:59–29:50
• Risks & Ethical Responsibilities – 31:01–33:08
• Challenges in Appropriation & Cultural Stewards – 34:10–36:12
• Therapist Training & Medical Models – 41:13–45:51
• Societal Acceptance & Bipartisan Support – 55:33–61:04
• Octopus Experiment and Call for Curiosity – 63:47–66:00

Tone & Conversation Style

The conversation is open, inquisitive, and deeply respectful—layering scientific explanation with ethical inquiry, personal narrative, cultural sensitivity, and a dash of wonder. Both Krista and Gül maintain a spirit of humility and caution, matching scientific rigor with empathy and social conscience.

Summary

This episode offers a nuanced, hope-filled, and also vigilant look at the frontier of psychedelic science. Dr. Gül Dölen’s research—spanning neuroplasticity, critical periods, and ethological curiosity—offers both a challenge to existing psychiatric models and a call for ethical stewardship. The conversation maps the possibility of radical healing through careful, guided integration of psychedelics, while never losing sight of inherent risks and responsibilities. The emerging bipartisan support and societal momentum around these medicines speak to their transformative potential—not just for individuals, but for culture at large. Most of all, the episode invites continued curiosity and responsible exploration, grounded in science and compassion.